People: Endo Health Solutions Inc (ENDP.OQ)
ENDP.OQ on NASDAQ Stock Exchange Global Select Market
39.04USD
11:31am EDT
39.04USD
11:31am EDT
Price Change (% chg)
$-0.01 (-0.03%)
$-0.01 (-0.03%)
Prev Close
$39.05
$39.05
Open
$39.01
$39.01
Day's High
$39.10
$39.10
Day's Low
$38.66
$38.66
Volume
65,986
65,986
Avg. Vol
526,816
526,816
52-wk High
$39.90
$39.90
52-wk Low
$25.01
$25.01
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Roger Kimmel |
66 | 2007 | Independent Chairman of the Board |
Rajiv De Silva |
46 | 2013 | President, Chief Executive Officer, Director |
Alan Levin |
50 | 2009 | Chief Financial Officer, Executive Vice President |
Camille Farhat |
43 | 2012 | President of American Medical Systems Inc. |
Ivan Gergel |
52 | 2008 | Executive Vice President - Research & Development, Chief Scientific Officer |
Caroline Manogue |
44 | 2004 | Executive Vice President, Chief Legal Officer, Secretary |
John DeLucca |
70 | 2006 | Independent Director |
Nancy Hutson |
63 | 2009 | Independent Director |
Michael Hyatt |
67 | 2000 | Independent Director |
William Montague |
66 | 2009 | Independent Director |
David Nash |
57 | 2011 | Independent Director |
Joseph Scodari |
60 | 2008 | Independent Director |
Jill Smith |
55 | 2012 | Independent Director |
William Spengler |
58 | 2008 | Independent Director |
Blaine Davis |
Senior Vice President - Corporate Affairs |
Biographies
| Name | Description |
|---|---|
Roger Kimmel |
Mr. Roger H. Kimmel is Independent Chairman of the Board of Endo Health Solutions Inc., (formerly Endo Pharmaceuticals Holdings Inc.), since May 30, 2007. Mr. Kimmel became Chairman of the Board upon the retirement of founder Carol A. Ammon on May 30, 2007. Mr. Kimmel had been a Director of Algos Pharmaceutical Corporation since July 1996 and became a Director of Endo following its merger with Algos in July 2000. Mr. Kimmel has been Vice Chairman of Rothschild Inc., an investment banking firm, since January 2001. Previously, Mr. Kimmel was a partner of the law firm Latham & Watkins for more than five years. Mr. Kimmel is also a director of PG&E Corporation, a public energy-based holding company. Mr. Kimmel has been Chairman of the Board of Trustees of the University of Virginia Law School Foundation (not- for-profit) since January 2009. He has been a public speaker on corporate governance issues and private equity transactions. |
Rajiv De Silva |
Mr. Rajiv De Silva is President, Chief Executive Officer, Director of Endo Health Solutions Inc., since March 18, 2013. Prior to joining Endo in March 2013, Mr. De Silva served as the President of Valeant Pharmaceuticals International, Inc. from October 2010 to January 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from January 2009 until January 2013. He was responsible for all specialty pharmaceutical operations, including sales and marketing, research and development, manufacturing and business development. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia/New Zealand. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. During this time, he played a key role at Novartis’ Vaccines & Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Principal at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva has been a Director of AMAG Pharmaceuticals, Inc. since February 2012. He holds a Bachelor of Science in Engineering, Honors from Princeton University, a Master of Science from Stanford University and a Master of Business Administration with Distinction from the Wharton School at the University of Pennsylvania. |
Alan Levin |
Mr. Alan G. Levin is Chief Financial Officer, Executive Vice President of Endo Health Solutions Inc. Prior to joining Endo, Mr. Levin worked with Texas Pacific Group, a private equity firm, and one of their start-up investments in Emerging Markets. Before that, he was Senior Vice President & Chief Financial Officer of Pfizer, Inc. where he worked for 20 years in a variety of executive positions of increasing responsibility, including Treasurer and Senior Vice President of Finance & Strategic Management for the company’s research and development organization. He received a bachelor’s degree from Princeton University and a master’s degree from New York University’s Stern School of Business. Mr. Levin is a certified public accountant and an Editorial Advisor for the Journal of Accountancy. He is a member of the Advisory Board of Celtic Therapeutics, a private equity fund. |
Camille Farhat |
Mr. Camille Farhat is President of American Medical Systems Inc., a subsidiary of Endo Health Solutions Inc. Mr. Farhat brings global experience from assignments in 10 countries and nine industries over 22 years. He is a business executive with a track record of revitalizing, turning around, and profitably growing businesses. Before joining Endo, Mr. Farhat held the position of General Manager of Baxter Pharmaceuticals & Technologies (BPT). Camille joined Baxter in February 2006 as General Manager of Global Infusion Systems. Prior to Baxter, Mr. Farhat was with Medtronic where he held the position of Vice President of Business Development after he was Global General Manager of Medtronic's Gastroenterology and Urology division. He spent 13 years with General Electric (GE) where he gained broad executive experience with assignments in many businesses, geographies, and functional areas, up to his final role with the company as General Manager for the Computed Tomography (CT) business. He holds a Master of Business Administration from Harvard University, a degree in European Union Studies from Institut National d'Etudes Politiques de Paris, and a Bachelor of Sciences (summa cum laude) in International Finance and Accounting from Northeastern University. |
Ivan Gergel |
Dr. Ivan P. Gergel, M.D., is Executive Vice President - Research & Development, Chief Scientific Officer of Endo Health Solutions Inc. Prior to joining Endo, Dr. Gergel was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc. Prior to that, Dr. Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute. He joined Forest in 1998 as Executive Director of Clinical Research following nine years at SmithKline Beecham, and was named Vice President of Clinical Development and Clinical Affairs in 1999. Dr. Gergel received his M.D. from the Royal Free Medical School of the University of London and an MBA from the Wharton School. Dr. Gergel is a member of the Board of Directors of Pennsylvania BIO, a member of PhRMA’ s Scientific and Regulatory Executive Committee, as well as a member of the Board of Directors of the PhRMA Foundation. |
Caroline Manogue |
Ms. Caroline B. Manogue is Executive Vice President, Chief Legal Officer, Secretary of Endo Health Solutions Inc. Prior to joining Endo in 2000 as Endo’s Senior Vice President, General Counsel and Secretary, she practiced law in the New York office of the law firm Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers & acquisitions, securities and corporate law. At Endo, she is responsible for all aspects of the company’s legal function, including securities law, litigation, government affairs, intellectual property and commercial law, as well as overseeing compliance with current laws and existing pharmaceutical company guidelines relating to, among other things, clinical, sales and marketing practices. In her capacity as Secretary, she is responsible for corporate governance matters and reports directly to the Board of Directors. Ms. Manogue received her J.D. from Fordham Law School and her B.A. cum laude from Middlebury College. She is the 2011-2012 Chairperson of the PhRMA Law Section, a member of the Board of Trustees of the Healthcare Institute of New Jersey (HINJ) and a member of HINJ’s Finance and Audit Committee. |
John DeLucca |
Mr. John J. DeLucca is Independent Director of Endo Health Solutions Inc., (formerly Endo Pharmaceuticals Holdings Inc.), since 2006. Mr. Delucca was Executive Vice President and Chief Financial Officer of the REL Consultancy Group, a business consulting firm, until his retirement in 2004. Prior to that, he served as Chief Financial Officer and Executive Vice President, Finance & Administration, of Coty, Inc., a fragrance and beauty products company, from 1999 to 2002. From 1993 to 1999, he was Senior Vice President and Treasurer of RJR Nabisco, Inc. During his career, he also served in executive positions for Hascoe Associates, Inc., The Lexington Group, the Trump Group, International Controls Corp., and Textron, Inc. He previously served as a Non-Executive Director and a member of the Audit Committee and Governance and Nominating Committee of Tier Technologies, Inc., a publicly traded payments solutions company. Mr. Delucca had also served as a Non-Executive Director and chair of the Audit Committee and a member of the compensation Committee of Germany-based Elster Group. |
Nancy Hutson |
Dr. Nancy J. Hutson, Ph.D., is Independent Director of Endo Health Solutions Inc., (formerly Endo Pharmaceuticals Holdings Inc.), since March 30, 2009. Dr. Hutson retired from Pfizer, Inc. in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer’s pharmaceutical R&D site, known as Groton/New London Laboratories, the R&D site of any pharmaceutical company. At Pfizer, she led 4,500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She currently is a director of Cubist Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc., and serves on the board of Planned Parenthood of Connecticut. |
Michael Hyatt |
Mr. Michael Hyatt is Independent Director of Endo Health Solutions Inc., since July 18, 2000. He is Chairman of Endo’s Transactions Committee and a member of Endo’s Nominating & Governance Committee. Mr. Hyatt had been a director of Algos Pharmaceutical Corporation since November 1996 and became a director of Endo following its merger with Algos in July 2000. Mr. Hyatt is currently a senior advisor to Irving Place Capital, a institutional private equity firm focused on making equity investments in middle-market companies. Until 2008, Mr. Hyatt was a Senior Managing Director of Bear Stearns & Co., Inc. |
William Montague |
Mr. William P. Montague is Independent Director of Endo Health Solutions Inc., (formerly Endo Pharmaceuticals Holdings Inc.), since February 27, 2009. Mr. Montague served as Chief Executive Officer of Mark IV Industries, Inc., a global diversified manufacturer of engineered systems and components for transportation infrastructure, vehicles and equipment, from November 2004 until his retirement on July 31, 2008 and as Director from March 1996. He joined Mark IV Industries in April 1972 as Treasurer/Controller, serving as Vice President of Finance from May 1974 to February 1986, then Executive Vice President and Chief Financial Officer from February 1986 to March 1996 and then as President from March 1996 to November 2004. Mr. Montague is also a director of Gibraltar Industries, Inc., a publicly traded manufacturer and distributor of products for the building and industrial markets. In February 2013, Mr. Montague became a director of Allied Motion Technologies Inc., a publicly traded company focused exclusively on serving the motion control market. |
David Nash |
Dr. David B. Nash, M.D., M.B.A., is Independent Director of Endo Health Solutions Inc., (formerly Endo Pharmaceuticals Holdings Inc.), since March 3, 2011. He is the founding dean of the Jefferson School of Population Health, located on the campus of Thomas Jefferson University in Philadelphia, Pennsylvania, having taken that position in 2008. Previously, Dr. Nash was the Chairman of the Department of Health Policy of the Jefferson Medical College from 2003 to 2008. Dr. Nash is internationally recognized for his work in outcomes management, medical staff development and quality-of-care improvement; his publications have appeared in more than 100 articles in journals. Dr. Nash serves on the Board of Directors of Humana Inc., one of the nation’s publicly traded health and supplemental benefits companies. |
Joseph Scodari |
Mr. Joseph C. Scodari is Independent Director of Endo Health Solutions Inc., (formerly Endo Pharmaceuticals Holdings Inc.), since 2008. Mr. Scodari was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, a diversified healthcare company, and a Member of Johnson & Johnson’s Executive Committee from March 1, 2005 until March 1, 2008. He joined Johnson & Johnson in 1999 as President of Centocor, Inc., a biotechnology company, when Johnson & Johnson acquired Centocor. At the time of that acquisition, he had been the President and Chief Operating Officer of Centocor and a member of Centocor’s Board of Directors since December 1997. In 2001, he was named Johnson & Johnson’s Company Group Chairman for the North American pharmaceutical business, and became a member of the Johnson & Johnson Pharmaceuticals Group Operating Committee. In 2003, Mr. Scodari was named Johnson & Johnson Company Group Chairman, Global Biopharmaceutical Business. Mr. Scodari is a director of Covance Inc., a publicly traded drug development service company. Prior to joining Centocor, Mr. Scodari served in various senior leadership roles at Sterling Drug and later, Rhone-Poulenc Rorer. |
Jill Smith |
Ms. Jill D. Smith is Independent Director of Endo Health Solutions Inc., since September 27, 2012. Ms. Smith has been international business leader for more than 25 years, including 16 years as a CEO of private and public companies in the technology and information services markets and was most recently chairman, CEO and president of DigitalGlobe Inc., a provider of satellite imagery products and services to governments and companies worldwide. Ms. Smith currently serves on the board of SoundBite Communications, Inc. a provider of cloud based customer communications and has served on the corporate boards of Germany-based Elster Group and DigitalGlobe (prior to her appointment as Chairman and CEO). In addition, Ms. Smith is a member of the board of Crittenton Women’s Union, among other past professional and trade association board positions. |
William Spengler |
Mr. William F. Spengler is Independent Director of Endo Health Solutions Inc., (formerly Endo Pharmaceuticals Holdings Inc.), since 2008. From November 2010 until February 2012, Mr. Spengler was President of ChromaDex Corporation, a publicly traded company that in the development of phytochemical and botanical reference standards and that discovers, develops and markets novel, natural ingredients. From July 2008 until November 2010, Mr. Spengler served as Executive Vice President and Chief Financial Officer of Smith & Wesson Holding Corporation, a safety, security, protection and sport. Until March 2008, he was Executive Vice President and Chief Financial Officer at MGI Pharmaceuticals Inc., an oncology- and acute care- focused biopharmaceutical company, where he had worked since 2005. Prior to joining MGI Pharma, Mr. Spengler was Executive Vice President and Chief Financial Officer at Guilford Pharmaceuticals Inc., a bioscience company, from July 2004 to October 2005. From 2002 to 2004, Mr. Spengler served as President, Chief Operating Officer and Director of Osteoimplant Technology, Inc., an orthopedic products company. Mr. Spengler was previously a Vice President of Finance at Black & Decker, and prior to that spent 14 years in various finance, planning and business development positions at Bristol Myers Squibb. |
Blaine Davis |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Roger Kimmel |
-- |
Rajiv De Silva |
-- |
Alan Levin |
2,489,500 |
Camille Farhat |
-- |
Ivan Gergel |
2,152,950 |
Caroline Manogue |
2,008,630 |
John DeLucca |
-- |
Nancy Hutson |
-- |
Michael Hyatt |
-- |
William Montague |
-- |
David Nash |
-- |
Joseph Scodari |
-- |
Jill Smith |
-- |
William Spengler |
-- |
Blaine Davis |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Roger Kimmel |
0 | 0 |
Rajiv De Silva |
0 | 0 |
Alan Levin |
9,954 | 70,350 |
Camille Farhat |
0 | 0 |
Ivan Gergel |
58,845 | 868,708 |
Caroline Manogue |
205,836 | 3,958,854 |
John DeLucca |
0 | 0 |
Nancy Hutson |
0 | 0 |
Michael Hyatt |
0 | 0 |
William Montague |
0 | 0 |
David Nash |
0 | 0 |
Joseph Scodari |
0 | 0 |
Jill Smith |
0 | 0 |
William Spengler |
0 | 0 |
Blaine Davis |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
GERGEL IVAN P |
8,690 | $0.00 |
NASH DAVID B |
408 | $0.00 |
KIMMEL ROGER H |
1,427 | $0.00 |
LEVIN ALAN G |
4,376 | $36.30 |
GERGEL IVAN P |
31,484 | $20.61 |
GERGEL IVAN P |
61,206 | $36.46 |
GERGEL IVAN P |
31,484 | $36.48 |
GERGEL IVAN P |
12,500 | $36.48 |
GERGEL IVAN P |
12,500 | $25.02 |
GERGEL IVAN P |
33,035 | $36.41 |
GERGEL IVAN P |
61,206 | $19.93 |
MANOGUE CAROLINE BERRY |
35,000 | $35.00 |
MANOGUE CAROLINE BERRY |
35,000 | $15.24 |
NASH DAVID B |
488 | $0.00 |
KIMMEL ROGER H |
1,707 | $0.00 |
LEVIN ALAN G |
14,683 | $0.00 |
NASH DAVID B |
670 | $30.80 |
RUDIO DANIEL A |
520 | $30.91 |
MANOGUE CAROLINE BERRY |
3,346 | $30.03 |
RUDIO DANIEL A |
322 | $29.88 |
HOLVECK DAVID P |
19,644 | $30.03 |
RUDIO DANIEL A |
448 | $29.88 |
GERGEL IVAN P |
7,168 | $30.03 |
GERGEL IVAN P |
1,573 | $28.09 |
GERGEL IVAN P |
1,509 | $28.09 |

